|Mr. Adam Sinding Steensberg M.D.||Pres & CEO||680.84k||N/A||1974|
|Mr. Ivan Mourits Moller||Chief Operating Officer||N/A||N/A||1972|
|Lani Pollworth Morvan||Investor Relations & Communications Officer||N/A||N/A||N/A|
|Mr. Mads Kronborg||Head of Investor Relations & Communication||N/A||N/A||N/A|
|Mr. Ravinder Chahil||Sr. VP & Gen. Counsel||N/A||N/A||N/A|
|Ms. Christina Sonnenborg Bredal||Sr. VP and Global Head of People & Organization||N/A||N/A||1985|
|Ms. Hanne Heidenheim Bak||Sr. Project Director, R&D Operations Mang. and Employee Representative Director||N/A||N/A||1953|
|Dr. Jens Damsgaard Mikkelsen M.D.||Head of Molecular Pharmacology||N/A||N/A||N/A|
|Dr. Danilo Verge||Head of Global Medical Affairs||N/A||N/A||N/A|
|Dr. David M. Kendall M.D.||Chief Medical Officer||N/A||N/A||1962|
Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company markets lixisenatide under the brand names of Adlyxin and Lyxumia; Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia, congenital hyperinsulinism, and post bariatric surgery hypoglycemia; and Dasiglucagon dual-hormone artificial pancreas for automated diabetes management. The company's pipeline includes Dasiglucagon that is in Phase III clinical trials for congenital hyperinsulinism. The company is also developing glepaglutide, a long acting GLP-2 analog, which is in Phase III clinical trials for the treatment of short bowel syndrome. Zealand Pharma A/S has collaboration agreements with Sanofi-Aventis Deutschland GmbH; Boehringer Ingelheim International GmbH; Alexion Pharmaceuticals, Inc.; and Beta Bionics, Inc. The company was incorporated in 1998 and is headquartered in Copenhagen, Denmark.
Zealand Pharma A/S’s ISS governance QualityScore as of 1 September 2022 is 3. The pillar scores are Audit: 8; Board: 2; Shareholder rights: 1; Compensation: 7.